JP2005503339A - 前立腺患者における健康関連クオリティオブライフ及び病気進行までの健康関連クオリティ適応時間の有利な調整 - Google Patents

前立腺患者における健康関連クオリティオブライフ及び病気進行までの健康関連クオリティ適応時間の有利な調整 Download PDF

Info

Publication number
JP2005503339A
JP2005503339A JP2002582924A JP2002582924A JP2005503339A JP 2005503339 A JP2005503339 A JP 2005503339A JP 2002582924 A JP2002582924 A JP 2002582924A JP 2002582924 A JP2002582924 A JP 2002582924A JP 2005503339 A JP2005503339 A JP 2005503339A
Authority
JP
Japan
Prior art keywords
trans
benzodioxol
pyrrolidine
carbonyl
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002582924A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005503339A5 (enExample
Inventor
シン，アミタブ
パドリー，ロバート・ジエイ
アシユラフ，タラツト
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Laboratories
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/832,752 external-priority patent/US20030022811A1/en
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Publication of JP2005503339A publication Critical patent/JP2005503339A/ja
Publication of JP2005503339A5 publication Critical patent/JP2005503339A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2002582924A 2001-04-11 2002-04-11 前立腺患者における健康関連クオリティオブライフ及び病気進行までの健康関連クオリティ適応時間の有利な調整 Pending JP2005503339A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/832,752 US20030022811A1 (en) 2001-04-11 2001-04-11 Favorable modulation of health-related quality of life and health-related quality-adjusted time-to-progression of disease in patients with prostate cancer
US11848602A 2002-04-08 2002-04-08
PCT/US2002/011397 WO2002085351A1 (en) 2001-04-11 2002-04-11 Favorable modulation of health-related quality of life and health-related quality-adjusted time-to-progression of disease in patients with prostate cancer

Publications (2)

Publication Number Publication Date
JP2005503339A true JP2005503339A (ja) 2005-02-03
JP2005503339A5 JP2005503339A5 (enExample) 2008-11-20

Family

ID=26816420

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002582924A Pending JP2005503339A (ja) 2001-04-11 2002-04-11 前立腺患者における健康関連クオリティオブライフ及び病気進行までの健康関連クオリティ適応時間の有利な調整

Country Status (10)

Country Link
EP (1) EP1379238A1 (enExample)
JP (1) JP2005503339A (enExample)
CN (1) CN1514727A (enExample)
AR (1) AR033465A1 (enExample)
BR (1) BR0205970A (enExample)
CA (1) CA2442591A1 (enExample)
IL (1) IL158071A0 (enExample)
MX (1) MXPA03009277A (enExample)
PE (1) PE20021032A1 (enExample)
WO (1) WO2002085351A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0219660D0 (en) 2002-08-23 2002-10-02 Astrazeneca Ab Therapeutic use
WO2004100991A1 (en) * 2003-05-15 2004-11-25 Universite Catholique De Louvain Use of endothelin-1 antagonists for improving cancer therapy
GB0403744D0 (en) 2004-02-20 2004-03-24 Astrazeneca Ab Chemical process
US20080085313A1 (en) * 2006-05-15 2008-04-10 Given Bruce D Methods and compositions for treatment of sleep apnea
JP2010536880A (ja) 2007-08-22 2010-12-02 ギリード・コロラド・インコーポレーテッド 糖尿病の合併症のための療法
CN117751099A (zh) * 2021-08-05 2024-03-22 中国药科大学 酰胺类化合物及其应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR200101234T2 (tr) * 1997-08-04 2002-06-21 Abbott Laboratories Endotelin antagonistleri.

Also Published As

Publication number Publication date
AR033465A1 (es) 2003-12-17
CA2442591A1 (en) 2002-10-31
EP1379238A1 (en) 2004-01-14
BR0205970A (pt) 2003-09-30
WO2002085351A1 (en) 2002-10-31
IL158071A0 (en) 2004-03-28
MXPA03009277A (es) 2004-03-10
PE20021032A1 (es) 2002-11-12
CN1514727A (zh) 2004-07-21

Similar Documents

Publication Publication Date Title
KR101381060B1 (ko) 4-아미노-2-(2,6-디옥소피페리딘-3-일)이소인돌린-1,3-디온의 제제
JP6479877B2 (ja) Ｊａｋ阻害剤の局所製剤
DE60029139T2 (de) Bupropion metabolite und verfahren zur deren synthese und verwendung
JP2009526821A (ja) 注意欠陥多動性障害治療用の新規な医薬組成物
TWI494293B (zh) 用於治療認知障礙之α-胺基醯胺衍生物
EP2813498B1 (en) Compounds for Alzheimer's disease
JP2010111693A (ja) アムロジピン及びアトルバスタチンを含む治療用の組み合わせ
JP2021183640A (ja) 活性化脂肪酸の治療有効量を使用する疾患の予防、処置および逆転
CN1473567A (zh) 包含阿伐他汀和抗高血压药的联合疗法
JP6528779B2 (ja) びまん性大細胞型ｂ細胞リンパ腫の予防および／または治療剤
JP2008538741A (ja) 鬱病の治療用及び／又は予防用の医薬組成物
US9238033B2 (en) Pharmaceutical composition containing KW-6002 and fluoxetine or paroxentine
TW201625268A (zh) 包含阿茲海默症之治療劑的有關神經細胞之軸索功能不全之疾患之治療劑
JP6824906B2 (ja) 併用療法
KR20140108707A (ko) (+)-2-[1-(3-에톡시-4-메톡시-페닐)-2-메탄술포닐-에틸]-4-아세틸아미노이소인돌린-1,3-디온의 제제
DE69607904T2 (de) Potenzierung von Serotonin-Wirkstoffresponz
US20030092757A1 (en) Favorable modulation of health-related quality of life and health-related quality-adjusted time-to-progression of disease in patients with prostate cancer
JP7590351B2 (ja) Ｐｒｍｔ５阻害剤を使用した癌の治療法
JP2005503339A (ja) 前立腺患者における健康関連クオリティオブライフ及び病気進行までの健康関連クオリティ適応時間の有利な調整
JP6131046B2 (ja) 抗癌剤により誘発される末梢神経障害を抑制する化合物
EP0915826A1 (en) Smooth muscle spasmolytic agents, compositions and methods of use thereof
JP6980655B2 (ja) 異所性脂肪蓄積治療用ａ３アデノシン受容体リガンド
WO2017204319A1 (ja) グルコシルセラミド合成酵素阻害剤
DE69709273T2 (de) Verwendung von PKC-Hemmern zur Herstellung eines Arzneimittels zur Behandlung von Sexualfunktionsstörungen
JP2008501023A (ja) 小児患者での癌の治療

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20041029

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080318

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20080616

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20080623

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080917

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20080917

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20081111